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Aims To evaluate whether stents as compared to balloon angioplasty reduce mortality
in patients with non-acute coronary artery disease.
Methods and results We identified randomized controlled trials comparing stents to
balloon angioplasty for the treatment of non-acute coronary artery disease by
searching major medical databases from 1979 to March 2002. Two independent
reviewers selected and extracted data from trials that had to report data on death
and myocardial infarction. Nineteen trials, with a total of 8004 patients, fulfilled
our inclusion criteria. For 1000 patients treated with stents rather than balloon
angioplasty, 3 (95% CI 0–6), 5 (95% CI 0–9), and 6 (95% CI -1–12) additional lives were
saved at 30 days, 6 and 12 months. At 12 months, for 1000 patients treated with stents
rather than balloon angioplasty 46 (95% CI 25–66) additional target vessel revasculari-
zations were avoided, but 25 (95% CI 15–34) additional bleeding complications with
need for blood transfusion or surgical intervention occurred. In sensitivity analysis 11
(95% CI 2–20) and 2 (95% CI -4–7) deaths were avoided per 1000 patients treated with
stents rather than PTCA in trials that routinely used compared to trials that did not use
glycoprotein IIb/IIIa inhibitors.
Conclusion In non-acute coronary disease stents may reduce overall mortality, but
this benefit seems to be limited to stents used in conjunction with glycoprotein IIb/IIIa
inhibitors. Stents compared to PTCA reduce target vessel revascularizations, but
increase the risk of bleeding complications.
© 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.
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Introduction
Since the introduction of the first stents in 19871 their
use in patients with coronary artery disease has steadily
increased. Today over 1 million coronary angioplasty
procedures are performed every year in the USA.2 In
Europe stents are used in more than 70% of these pro-
cedures.3 Clinical trials have shown that stents reduce
restenosis and revascularization compared to simple
balloon angioplasty.4–6
The introduction of sirolimus-and paclitaxel eluting
stents is another breakthrough in the treatment of cor-
onary artery disease. In a recent trial, 27% of patients
treated with conventional uncoated stents, but none of
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the patients treated with sirolimus-eluting stents devel-
oped restenosis.7 Major cardiac events were significantly
reduced in the first year following treatment, but this
effect was entirely due to a higher revascularization rate
in the conventional stent group. Similarly, restenosis and
intimal hyperplasia was more effectively reduced by
paclitaxel-eluting as compared to conventional stents in
another recent randomized trial.8 However, it is still not
known whether routine use of stents rather than balloon
angioplasty in non-acute coronary heart disease reduces
mortality and other clinical outcomes such as myocardial
infarction.
In a meta-analysis of randomized controlled trials, we
investigated whether routine use of stents rather than
balloon angioplasty reduces mortality and improves clini-
cal outcome in patients with non-acute coronary artery
disease.
Methods
Data search and trial selection
We searched Medline, Embase, Pascal, Index medicus, the
Cochrane library and abstracts from cardiology conferences
from 1979 to March 2002 to identify all randomized controlled
trials in non-acute coronary artery disease that compared
stents with balloon angioplasty. We used the following search
terms: Angioplasty-transluminal-percutaneous-coronary, Stents,
Randomized-controlled-trials, Clinical-trials, Coronary-artery-
dilatation, Transluminal-coronary-angioplasty, Random. In
addition, we searched all references of relevant articles for
additional trials and if necessary, contacted authors of
identified trials to ask for additional information.
Two reviewers independently selected the relevant trials and
resolved disagreement by consensus. The same reviewers
extracted data from all trials that fulfilled our inclusion criteria.
Inclusion- and exclusion criteria
Trials were included if they met the following criteria: random-
ization to stents or balloon angioplasty prior to the invasive
procedure, intervention in native coronary arteries, reporting
death or myocardial infarction, and follow-up of at least 6
months. We excluded trials in patients with acute myocardial
infarction where angioplasty was done within 48 h after diag-
nosis, trials that exclusively randomized patients to provisional
stenting and trials where patients were randomized after
angioplasty only.
Outcomes
The primary outcome was mortality at 30 days (including
in-hospital mortality), and at 6 and 12 months after the inter-
vention. Secondary outcomes were myocardial infarction, cor-
onary artery bypass grafting (CABG), a composite outcome of
death and myocardial infarction, target vessel revasculariz-
ation, and bleeding complications with need of transfusion or
surgery.
Assessment of study quality
Two reviewers independently assessed the quality of each
included trial according to the following criteria: concealment
of treatment allocation, blinded outcome assessment, and full
description of follow-up. We summarized the quality rating and
used a modified Jadad score (Table 1).9 The score gives one
point to each of five items (random allocation, blinding, blinded
outcome assessment, full description of all losses of follow-up
and withdrawals, and loss to follow-up <10%) if present. One
additional point is given if randomization is concealed and one if
double-blinding is appropriate. Since blinding to stent or balloon
angioplasty was not possible, the score could range from 0 to 5
points. Agreement between the two reviewers was assessed
by calculating proportions of specific agreement for positive
and negative ratings.10 Disagreement between reviewers was
resolved by consensus.
Examination of publication bias
We used a plot of standardized effect against precision to test
for the presence of publication bias.11
Data aggregation and sensitivity analysis
We used STATA 7.0 (Stata Corporation, Texas, USA) statistical
software to calculate summary risk differences using a fixed
effect model. While meta-analyses are often carried out on a
relative scale, the risk difference scale is appealing for rare
events because of its immediate interpretability and because
trials with zero events in both treatment groups can be included
in the analysis.12 In our analysis, the use of summary risk
differences was a reasonable approach since there was little
difference between trials in event rates in the control
group.13,14 For easier interpretation, we report differences in
event rates per 1000 patients. In addition, we report Peto odds
ratios for the primary outcome. Simulation suggests that with
rare events, meta-analysis underestimates the true effect of
treatment over control, but Peto odds ratios are the least biased
and most powerful method of pooling trial results among the
methods in common use.15,16 When events are at least moder-
ately rare (i.e. one or two per 1000), odds ratios are a close
approximation to the relative risk.12
To explore the stability of the overall treatment effect, we
compared the primary outcome in predefined subgroups.17,18
These subgroups were: different types of stents, intervention in
vessels with large (≥3 mm) and small (<3 mm) diameters, differ-
ent post-interventional antithrombotic/anticoagulant drug regi-
mens, and use of glycoprotein IIb/IIIa inhibitors. In order to
account for an any time-related effect, we performed an
additional sensitivity analysis comparing trials starting enrol-
ment of patients before the year 1996 and trials starting
enrolment in 1996 or later.
Role of the funding source
The funding source was not involved in study design, collection,
analysis, or interpretation of data and had no impact on writing
the manuscript or on the decision to submit the paper.
Results
Trials characteristics
Of 602 potentially relevant publications, 24 met our
inclusion criteria (Fig. 1). Five of these publications were
long-term follow-up reports of previously published
trials5,19–22 and so 19 trials with a total of 8004 patients
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Table 1 Baseline characteristics and type of intervention in randomised controlled trials comparing stenting to balloon angioplasty (BA)
Target vessel
Author (year) Intervention
and number
of
individuals
Mean
age
(±SD)
Male
(%)
Previous
MI (%)
Stenosis
(mean
%)
%
LAD
%
LCX
%
RCA
Stent type Differences in
Postinterventional
Antithrombotic/
Anticoagulant Therapy
Bleeding
compli-
cationsa
(%)
Successful
dilatationb
(%)
Crossover
(%)
Quality
score
Fischman 19944 Stent 205 60±10 83 37 75 47 16 37 Palmaz–Schatz Dipyridamol 75 mg/day 9 96 3 2
BA 202 73 36 75 48 13 39 and warfarin for 1 month in
stent-group
5 90 7
Serruys 199430 Stent 259 57±10 80 20 64 64 13 23 Palmaz–Schatz No difference 14 98 5 4
BA 257 82 19 64 62 10 28 3 97 5
Eeckhout 199656 Stent 42 58±4 88 36 72 0 0 100 Wiktor Aspirin 100 mg/day in PTCA 21 95 2 4
BA 42 74 38 71 0 0 100 Aspirin
325 mg/day+dipyridamol
75 mg/day in stent group
0 93 7
Versaci 199736 Stent 60 57±10 92 28 77 100 0 0 Palmaz–Schatz Warfarin for 3 months in 7 95 0 4
BA 60 83 29 78 100 0 0 stent-group 0 93 3
Serruys 199834 Stent 413 55±10 77 25 63 50 19 31 Palmaz–Schatz Ticlopidine 250 mg/day for
4 weeks in stent group only
1 99 0 5
BA 410 80 28 63 52 19 30 1 99 19
Topol 19985 Stent 794 60±11 75 50 Palmaz–Schatz Abciximab for all, 5 97 4 3
BA 796 75 49 ticlopidine 250 mg bid in
stent-group only
5 81 10
Betriu 199935 Stent 239 59±7 87 32 74 51 14 26 Palmaz–Schatz Dipyridamol 100 mg 4 95 1 4
BA 233 85 32 73 54 13 30 tid+warfarin for 2 to
3 months in stent-group only
1 84 37
Buller 199757 Stent: 202 58±11 84 67 100 38 21 46 Heparin-coated Ticlopidin in 57% of NA 95 2 4
BA 208 80 67 100 38 13 48 PTCA-and 93% of
stent-group
NA 88 10
Dangas 199929 Stent: 31 62±13 69 79 42 Palmaz–Schatz Ticlopidine for 2 to 4 weeks
in stent group only
NA 90 2 4
BA 66 69 76 19 NA 45 30
Niazi 199926 Stent 96 55±11 83 59 82 51 29 20 Jo-2 heparin-coated No information NA 1
BA 106 74 62 80 46 34 20 NA
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balloon
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Table 1 (continued)
Target vessel
Author (year) Intervention
and number
of
individuals
Mean
age
(±SD)
Male
(%)
Previous
MI (%)
Stenosis
(mean
%)
%
LAD
%
LCX
%
RCA
Stent type Differences in
Postinterventional
Antithrombotic/
Anticoagulant Therapy
Bleeding
compli-
cationsa
(%)
Successful
dilatationb
(%)
Crossover
(%)
Quality
score
Di Mario 200031 Stent 370 61±11 75 40 69 41 24 35 Not specified Ticlopidine 250 mg bid for 4
weeks in stent group only
NA 100 0 2
BA 365 73 38 69 38 23 39 NA 57 11
Fluck 200033 Stent: 154 58±9 76 68 Wiktor Warfarin and later ticlopidin
in stent group only
6 96 7 4
BA 146 76 70 2 96 26
Kastrati 200025 Stent 204 66±11 78 35 76 42 38 20 Multi-link Abciximab for all, 4 99 0 2
BA 200 76 39 78 40 41 20 ticlopidine for 4 weeks in
stent-group, for 2 weeks in
balloon angioplasty-group
1 99 57
Park 200027 Stent 60 61±8 62 15 77 45 33 22 NIR Ticlopidine 250 mg bid for 1
month in stent group only
NA 100 2 3
BA 60 65 10 74 55 30 15 NA 100 13
Weaver 20006 Stent: 230 61 75 44 89 32 21 45 Palmaz–Schatz No difference NA 89 3 3
BA 249 72 41 89 33 20 47 NA 78 23
Witkowski 200032 Stent 192 52±11 74 49 78 60 13 27 Palmaz–Schatz No difference 0 98 0 3
BA 196 72 42 77 56 15 29 0 99 20
Doucet 200123 Stent: 169 60±11 66 32 63 43 34 23 Be-stent Artist Ticlopidine 250–500 mg/day NA 98 4 3
BA 182 67 35 62 47 34 20 for 1 month in stent-group
only
NA 98 17
Koning 200128 Stent 192 62±10 73 32 68 24 19 10 Be-stent small Ticlopidine 500 mg/day in
stent group only
0 98 4 3
BA 189 79 43 66 26 22 13 0 94 14
Moer 200124 Stent 74 63±11 67 42 59 38 46 16 Heparin-coated Thienopyridine for 4 weeks NA 100 NA 4
BA 71 73 46 57 39 44 17 instent-grouponly NA 96 NA
BA=balloon angioplasty; NA=not available
aNeed for blood transfusion or surgical intervention.
bAs defined by individual trial criteria.
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were included in our meta-analysis (Table 1). Six differ-
ent stent types were used in the 19 trials. In 13 trials
the target vessel size was ≥3 mm, and in six trials
<3 mm.23–28 Three trials included only patients with
stable coronary artery disease,29–31 the remaining trials
included patients with stable and unstable angina.
Definitions of acute myocardial infarction varied
across trials. Only four trials mentioned pre-specified
criteria for the need of target vessel revascularization
(Table 2).
Only three trials used the same post-
interventional antithrombotic/anticoagulant therapy in
both groups.6,30,32 All other trials used a more aggressive
post-interventional therapy in the stent group.
Only two trials used a glycoprotein IIb/IIIa inhibitor
(abciximab) as a co-intervention in both treatment
arms.5,25 The EPISTENT-trial had three treatment arms:
we used data from two arms-stents with abciximab and
PTCA with abciximab.5 We did not use data from the
third arm (stents with placebo) because there was no
comparison group (balloon angioplasty with placebo).
Plots of standardized effects against precision indi-
cated a low probability for the presence of publication
bias (P=0.28).11
Agreement on quality rating
Proportions of specific agreement for positive and nega-
tive ratings were 0.92 and 0.94 for concealment of treat-
ment allocation, 0 and 0.83 for blinded outcome
assessment, and 0.91 and 0.75 for full description of loss
of follow-up. Proportions of specific agreement give the
probability that one assessment is positive (or negative)
given that the other assessment is also positive (or nega-
tive). Few trials were thought to have blinded outcome
assessment by one reviewer or the other, and reviewers
never agreed; hence the positive specific agreement of
zero for this item. Both reviewers concluded that all
trials lost 10% or fewer patients to follow-up and that all
trials had open intervention.
Methodologic quality of trials
Random allocation was concealed in 13 trials and possibly
concealed in the other six trials.5,27,30,32–34 In all trials,
interventions were not blinded for obvious reasons. After
consensus, no trial was found to explicitly mention
blinded outcome assessment. In all trials, follow-up data
were reported for at least 90% of the patients. In all but
five trials, a full description of follow-up and withdrawals
was given.4,26,31,34,35
Clinical outcomes
Primary outcome
At 30 days, three (95% CI 0 to 6) additional lives
were saved per 1000 patients treated with stents
rather than balloon angioplasty (Table 3, Fig. 2). Early
deaths occurred only in six of 19 trials. For these
six trials, the odds ratio for mortality with stents
rather than balloon angioplasty was 0.34 (95% CI 0.15–
0.81).
Fig. 1 Flow diagram of systematic review.
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At 6 months, deaths had occurred in 16 trials. On
average 5 (95% CI 0 to 9) additional lives were saved per
1000 patients treated with stents rather than balloon
angioplasty. The odds ratio for mortality with stents
rather than balloon angioplasty was 0.57 (95% CI 0.34–
0.96).
Seven trials reported mortality data at 12
months.4,17,20,29,31,32,34 Six (95% CI −1 to 12) additional
lives were saved per 1000 patients treated with stents
rather than balloon angioplasty. The odds ratio for mor-
tality with stents rather than balloon angioplasty was
0.62 (95% CI 0.36–1.05). In each analysis, there was no
evidence of heterogeneity (P>0.1).
Secondary outcomes
At 30 days there was no evidence from summary
risk differences that stents were superior to balloon
angioplasty for myocardial infarction, CABG, target
Table 2 Endpoint definitions and policy for repeated angiography in included trials
Definition of endpoints
Author (year) Myocardial infarction Need for target vessel
revascularization
Systematically
repeated
angiography
Fischman 19944 New pathological Q waves or a creatine kinase level
or MB fraction of at least twice upper limit of normal
Restenosis of target lesion in
association with recurrent
angina or in objective
evidence of ischaemia
Yes
Serruys 199430 New pathological Q waves or increase in creatine
kinase more than twice normal value plus
pathological increase in myocardial isoenzymes
Not prespecified Yes
Eeckhout 199656 Not defined Not prespecified Yes
Versaci 199736 Definite electrocardiographic changes and
documentation of abnormal cardiac enzyme levels
Not prespecified Yes
Serruys 199834 New pathological Q waves or increase in creatine
kinase more than twice normal value plus
pathological increase in myocardial isoenzymes
Not prespecified Yes
Topol 19985 New pathological Q-waves or increase in creatine
kinase or its MB isoenzyme to at least twice the
upper limit of normal
Not prespecified No (34% of patients)
Betriu 199935 New pathological Q waves or increase in creatine
kinase/CK-MB levels at least twice upper limit of
normal
Not prespecified Yes
Buller 199957 CK-MB elevation above normal range Not prespecified Yes
Dangas 199929 Not defined Not prespecified No (62% of patients)
Niazi 199926 Not defined Not prespecified Yes
Di Mario 200031 New pathological Q waves in territory of treated
artery or increase in creatine kinase MB fraction
Occlusion or restenosis at site
of initial lesion or within
5 mm
No
Fluck 200033 New pathological Q waves or increase in creatine
kinase to at least twice upper limit of normal
Not prespecified Yes
Kastrati 200025 New pathological Q waves or increase in creatine
kinase or its MB isoenzme to at least three times
upper limit of normal
Angiographic restenosis and
symptoms or signs of
ischaemia
Yes
Park 200027 New electrocardiographic changes or chest pain
≥30 min and increase in cardiac enzymes more than
three times upper limit of normal
Not prespecified Yes
Weaver 20006 New pathological Q waves or symptoms associated
with rise in creatine kinase or CK-MB to more than
twice normal values
Not prespecified No
Witkowski 200032 New pathological Q wave and/or creatine kinase or
MB fraction at least twice upper limit of normal
Not prespecified Yes
Doucet 200123 New pathological Q waves or elevation of creatine
kinase to greater than twice upper limit of normal
with elevated MB fraction
Recurrent angina or signs of
ischaemia
Yes
Koning 200128 Not defined Not prespecified Yes
Moer 200124 Two of three criteria: prolonged chest pain of
cardiac origin not relieved by nitroglycerin, rise in
creatine kinase more than twice upper limit of
normal, or new pathological Q waves
Not prespecified Yes
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vessel revascularization, and the composite outcome of
death and myocardial infarction (Table 3).
At 6 months, 55 (95% CI 40 to 71) target vessel
revascularizations were avoided per 1000 patients
treated with stents rather than balloon angioplasty.
Summary risk differences for myocardial infarction and
CABG suggested some benefit from stents over balloon
angioplasty, but these differences were not statistically
significant.
At 12 months, 46 (95% CI 25 to 66) target vessel
revascularizations were avoided per 1000 patients
treated with stents rather than balloon angioplasty, and
10 (95% CI 2 to 20) additional deaths or myocardial
infarctions were prevented for 1000 patients treated
with stents rather than balloon angioplasty. Summary risk
differences at 12 months indicated benefit from stenting
for all secondary outcomes–with the exception of CABG–
but were not statistically significant. In each analysis,
there was no evidence of heterogeneity (P>0.1).
Data on post-interventional bleeding complications
with need for blood transfusion or surgical intervention
were available from 11 trials. The bleeding complication
rate ranged from 0 to 21% in patients randomized to
stenting, and from 0 to 5% in patients randomized to
balloon angioplasty (Table 1). On average, there were 25
(95% CI 15 to 34) additional bleeding complications per
1000 patients treated with stents rather than balloon
angioplasty (test of heterogeneity P>0.1).
Sensitivity analyses
With few early deaths and few trials reporting 12-month
mortality, sensitivity analysis for the primary out-
come was only appropriate at 6 months. We compared
trials using different stent types, trials with interven-
tions in large and small vessels, trials with different
post-interventional antithrombotic/anticoagulant drug
therapies in both treatment arms and trials routinely
using respectively not using glycoprotein IIb/IIIa
inhibitors.
The average number of additional lives saved per 1000
patients treated with stents rather than PTCA was: five
(95% CI 0 to 10) in trials using Palmaz–Schatz stents and
four (95% −5 to 10) in trials using other stents; five (95% CI
0 to 10) in trials with intervention in large vessels and five
(95% CI −5 to 20) in trials with intervention in smaller
vessels; six (95% CI 0 to 10) in trials with more aggressive
post-interventional antithrombotic/anticoagulant drug
therapies in the stent group and one (95% CI −7 to 9) in
those three trials with identical post-interventional
therapies in both groups;5,28,30; 11 (95% CI 2 to 20) in
those two trials5,25 routinely using a glycoprotein IIb/IIIa
inhibitor in both treatment groups and two (95% CI −4 to
7) in all other trials not routinely using a glycoprotein
IIb/IIIa inhibitor; −1 (95% CI −9 to 7) in trials starting
patient enrolment before 1996 and seven (95% CI 1 to 13)
in trials starting patient enrolment in 1996 or later (test
of heterogeneity for all comparisons P>0.1).
In order to differentiate between the effects of time-
related improvements in stenting technique and the use
of a glycoprotein IIb/IIIa inhibitors, we repeated our
analysis of trials enrolling patients from 1996 and later
after exclusion of those two trials routinely using glyco-
protein IIb/IIIa inhibitors. By doing so, the average
number of additional lives saved per 1000 patients
treated with stents rather than PTCA was four (95% CI −3
to 11).
Discussion
Our meta-analysis shows that routine use of stents rather
than balloon angioplasty reduces overall mortality at 6
months in patients with non-acute coronary artery dis-
ease. This benefit, however, is small and corresponds to
five (95% CI 0 to 9) additional saved lives per 1000
patients treated. The benefit seems to persist at 12
months with six (95% CI −1 to 12) additional saved lives
per 1000 patients. At 12 months, patients treated with
stents rather than balloon angioplasty required between
25 and 66 fewer target vessels revascularizations per
1000 patients treated. This benefit, however, is tem-
pered by a higher risk of post-interventional bleedings
(15 to 34 additional bleedings per 1000 patients treated
with stents rather than balloon angioplasty).
The evidence that stents reduce mortality is weaker
when measured with risk differences than when
measured with odds ratios. Simulation suggests that both
measures will underestimate the true effect of stents
Table 3 Additional events prevented per 1000 patients treated with stents rather than balloon angioplasty in non-acute coronary
artery disease (test for heterogeneity P>0.1 for all comparisons)
Additional events prevented per 1000
(n= number of trials)
30 days
(95% CI) n=19
6 months
(95% CI) n=16
12 months
(95% CI) n=7
Primary outcome
Mortality 3 (0 to 6) 5 (0 to 9) 6 (−1 to 12)
Secondary outcomes
Revascularisation of target vessel 3 (−2 to 8) 55 (40 to 71) 46 (25 to 66)
Myocardial infarction 1 (−7 to 9) 2 (−7 to 10) 10 (−4 to 20)
Coronary artery bypass grafting −1 (−6 to 4) 3 (−5 to 10) 0 (−10 to 10)
Myocardial infarction and death 4 (−4 to 10) 7 (−4 to 20) 10 (2 to 20)
Severe bleeding complications (n=11) −25 (−15 to −34)
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rather than balloon angioplasty.15 While Peto odds ratios
may be less biased than risk differences when events are
rare, the implications of excluding trials with no events in
both groups has never been fully investigated.12 Using
risk differences, which include such trials, is therefore a
conservative approach.
Following a comprehensive literature search, we
included additional unpublished data from individual
trials by contacting authors of published trials to provide
information not readily available form the published
trials and of one trial that had been published only in
abstract form.26 We have no evidence of a publication
bias, although such a bias is always possible. We explored
heterogeneity between trials according to a priori
defined criteria but found no evidence for heterogeneity.
A lack of power could be a reason for our failure to detect
heterogeneity. The usual test for heterogeneity has low
power,37 particularly in meta-analyses of rare events.12
However, various clinical trials comparing different stent
types have not shown any difference on clinical outcomes
such as mortality and reinfarction rates.38–44 There may
be a higher risk of restenosis and revascularization with
the Gianturco–Roubin flex stent,45 but this stent was not
used in any of the trials in our analysis.
Given that stents seem to be associated with a lower
mortality than balloon angioplasty, we would have
expected a lower rate of myocardial infarction in
patients treated with stents. Possibly, stents reduce
acute plaque rupture of high-risk lesions and so reduce
sudden death, but have less effect on non-fatal myo-
cardial infarction. Unfortunately, we do not have the
necessary data on sudden death to test this hypothesis.
This meta-analysis has some limitations. Cross-over
rates from balloon angioplasty to stents in the included
trials were substantial and ranged from 0 to 57% (Table
1). Thus, we may underestimate the true effects of
stents. None of the included trials were found to report
blinded outcome assessment. While blinded outcome
assessment is irrelevant for mortality, the primary end-
point of our study, its absence limits the reliability of
results for the secondary outcomes.
Pre-specified comparisons for relevant subgroup
analysis of stent types and vessel size remained incon-
clusive due to lack of power. Only three trials used the
same post-interventional antithrombotic/anticoagulant
therapy in both groups.6,30,32 All other trials used a more
aggressive post-interventional therapy in the stent
group. Our sensitivity analysis lacked power to detect
what could be a clinically significant difference in mor-
tality between trials with balanced and unbalanced co-
intervention. Therefore, we can not be sure that the
reduced mortality in patients treated with stents is really
due to stenting and not to unbalanced co-intervention.
The beneficial effect of stenting on mortality was only
seen in trials that started patient enrolment in 1996 or
later. This implies that advances in stenting technique
over the past few years may account for the reduction in
mortality. However, the concomitant use of glycoprotein
IIb/IIIa inhibitors seems to be the most important factor
responsible for the observed benefit of stenting on mor-
tality as demonstrated by our sensitivity analysis. Even
modern stenting techniques do not seem to reduce mor-
tality in comparison to balloon angioplasty in the absence
of concomitant use of a glycoprotein IIb/IIIa inhibitor.
Importantly, the concomitant use of glycoprotein IIb/IIIa
inhibitors does not seem to be associated with a
higher risk of bleeding complications. In the Epistent
trial5 major bleeding episodes were not higher in
Fig. 2 Additional lives saved per 1000 patients treated with stents as compared to balloon angioplasty in non-acute coronary artery disease (BA).
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patients treated with stents or balloon angioplasty plus
abciximab than in patients treated with stents plus
placebo.
The generally higher bleeding risk associated with
stenting observed in this meta-analysis may be due to
inclusion of earlier trials that used more aggressive anti-
coagulant therapy. Recently, high levels of procedural
anticoagulation with heparin were found to increase
haemorrhagic complications without improving clinical
outcome in cardiac patients treated with stents.46 Based
on these results, activated clotting times within a range
of 150 to 275 s seem to be associated with the lowest risk
of bleeding complications.
The external validity of our findings may be limited.
Many trials were conducted in specialized high volume
centres and some of them included highly pre-selected
patients. Therefore, our results may not necessarily
apply to patients treated in other centres or settings. We
were not able to get individual patient data and there-
fore unable to evaluate the effects of stenting in import-
ant subgroups such as women, diabetic and elderly
patients. Women, diabetic and elderly patients were
clearly under-represented in the trials included into our
meta-analysis. More data on the effects of stenting in
these patients are required, especially in the elderly,
since angioplasty is increasingly used in older patients
with severe angina because it is less invasive than bypass
surgery.
We excluded trials that exclusively randomized
patients to provisional stenting, a technique that may be
less effective, but also less costly than routine stenting.47
Finally, the trials included into our meta-analysis were of
relatively short duration and there is a clear need for
more data on the long-term benefits of stents in coronary
angioplasty. Cohort studies and national or regional
registries could be used to collect this important
information.
A recent meta-analysis comparing routine coronary
stenting to balloon angioplasty concluded that stenting is
safe but probably not associated with important reduc-
tions in rates of mortality and acute myocardial infarc-
tion.48 However, this meta-analysis also included trials
that randomized patients to stents only after balloon
angioplasty had already been performed successfully.
This may lead to an underestimation of the true effects
of stenting since only patients with optimal balloon
angioplasty results served as controls. Furthermore, the
beneficial effect of the conjunctive use of glycoprotein
IIb/IIIa inhibitors to stents was missed, because no evalu-
ation of the impact of different antithrombotic co-
interventions was performed in that study. Another
recent meta-analysis that included data derived from
stent registries failed to demonstrate any difference in
mortality and infarction rates between patients treated
by stenting and balloon angioplasty.49 Inadequate power
due to insufficient sample size and lack of inclusion of
trials using glycoprotein IIb/IIIa inhibitors may explain
why no significant differences were observed in that
meta-analysis.
A meta-analysis comparing stents to balloon angi-
oplasty in patients with acute myocardial infarction and
with similar follow-up times failed to show any statisti-
cally significant difference in mortality (OR 1.04, 95% CI
0.75 to 1.44 for stents versus balloon angioplasty).50 This
could be due to the higher baseline risk of procedure- and
non-procedure-related mortality in acute compared to
non-acute coronary artery disease.
Stent technology has developed considerably over the
last few years. There is now a broad variety of stents with
different physical and antithrombotic properties. Clinical
trials are needed comparing different stent types or
stents with and without new co-interventions such as
drug-eluting stents or endoluminal beta-emitting radia-
tion therapy.7,8,51 Trials with longer follow-up are
needed comparing stents with other promising revascu-
larization procedures such as minimally invasive bypass
surgery.52 Some cost-effectiveness studies have clearly
favoured stents over balloon angioplasty53 while others
have been inconclusive.54,55 It is clear that stents will
become more economically attractive as their in-hospital
costs decrease. New stent types are likely to be
associated with higher in-hospital cost and so cost-
effectiveness analyses will be needed to justify their use.
In conclusion, routine use of stents rather than balloon
angioplasty in the treatment of non-acute coronary
artery disease is associated with a reduced risk of both
mortality and revascularization up to 6 months of follow-
up. The benefit on mortality seems to be limited to
stenting with concomitant use of glycoprotein IIb/IIIa
inhibitors. These benefits outweigh a higher risk of post-
interventional bleeding complications in patients treated
with stents.
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